Published in Lancet on July 29, 2000
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab (2010) 2.99
The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol (2005) 2.39
Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis (2004) 1.86
Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis (2007) 1.39
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis (2001) 1.25
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J (2005) 1.24
Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics (2008) 1.22
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics (2008) 1.20
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis (2012) 1.19
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol (2008) 1.19
The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther (2009) 1.17
Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia (2009) 1.13
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab (2008) 1.13
Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis (2014) 1.10
The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol (2013) 1.09
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet (2012) 1.09
Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther (2009) 1.06
Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis (2013) 1.04
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One (2012) 1.04
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis (2012) 1.03
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis (2011) 1.03
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis (2011) 1.00
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis (2014) 0.99
Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. J Inherit Metab Dis (2011) 0.99
Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med (2011) 0.92
Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis (2011) 0.91
Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol (2008) 0.90
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther (2012) 0.89
Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis (2014) 0.88
Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol (2007) 0.87
Expression systems and species used for transgenic animal bioreactors. Biomed Res Int (2013) 0.85
Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease. Ther Clin Risk Manag (2009) 0.85
Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J Inherit Metab Dis (2011) 0.83
Adult onset glycogen storage disease type II (adult onset Pompe disease): report and magnetic resonance images of two cases. Skeletal Radiol (2009) 0.82
Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis (2016) 0.82
A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther (2014) 0.82
Progress and problems when considering gene therapy for GSD-II. Acta Myol (2007) 0.81
iPS cell modeling of cardiometabolic diseases. J Cardiovasc Transl Res (2012) 0.80
Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc Natl Acad Sci U S A (2004) 0.80
Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study. Eur J Pediatr (2014) 0.79
Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study. Orphanet J Rare Dis (2016) 0.78
Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep (2015) 0.78
Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol (2016) 0.77
A conceptual disease model for adult Pompe disease. Orphanet J Rare Dis (2015) 0.75
Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting. Drug Des Devel Ther (2017) 0.75
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. Mol Ther (2017) 0.75
Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy. Neuromuscul Disord (2012) 0.75
Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease. Acta Neuropathol Commun (2015) 0.75
A review of treatment of Pompe disease in infants. Biologics (2007) 0.75
Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease. Mol Genet Metab Rep (2017) 0.75
Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease. JIMD Rep (2015) 0.75
Initiation of ECMO for ventilator-dependent respiratory failure in an infant with Pompe's. Pediatr Surg Int (2014) 0.75
Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease. Front Plant Sci (2017) 0.75
Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inherit Metab Dis (2014) 0.75
New names for old disciplines. J Inherit Metab Dis (2002) 0.75
Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO J (1988) 2.44
Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A (1982) 2.39
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature (1993) 2.36
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain (2005) 2.25
A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics (2001) 2.10
Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet (1995) 1.81
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet (1999) 1.76
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.72
Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord (2010) 1.62
Unapproved and off-label use of drugs in a children's hospital. N Engl J Med (2000) 1.62
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology (2007) 1.61
Introduction of a viral thymidine kinase gene and the human beta-globin gene into developmentally multipotential mouse teratocarcinoma cells. Proc Natl Acad Sci U S A (1980) 1.58
Transesophageal echocardiographic monitoring of interventional cardiac catheterization in children. J Am Coll Cardiol (1991) 1.56
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest (1987) 1.45
Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem (1985) 1.43
Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology (2004) 1.37
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther (1998) 1.36
Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology (2005) 1.35
Late-onset globoid cell leucodystrophy (Krabbe's disease). Clinical and genetic delineation of two forms and their relation to the early-infantile form. Neuropediatrics (1985) 1.33
Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem (1993) 1.32
Tay-Sachs and Sandhoff's disease: intergenic complementation after somatic cell hybridization. Exp Cell Res (1974) 1.32
TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet (2001) 1.31
Characterization of the human lysosomal alpha-glucosidase gene. Biochem J (1990) 1.26
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis (2001) 1.25
An additional measure for quantifying antibiotic use in hospitals. J Antimicrob Chemother (2005) 1.25
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J (1990) 1.24
Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet (1983) 1.22
The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry (1989) 1.22
Determination of Gaucher's disease phenotypes with monoclonal antibody. Clin Chim Acta (1983) 1.22
Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol (1999) 1.21
Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet (1978) 1.20
Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun (1994) 1.17
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord (2008) 1.15
Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem (1991) 1.15
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet (1998) 1.14
The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet (1994) 1.14
Biosynthesis and intracellular transport of alpha-glucosidase and cathepsin D in normal and mutant human fibroblasts. Eur J Biochem (1985) 1.13
X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course. Ann Neurol (1993) 1.12
Genetic heterogeneity in GM1-gangliosidosis. Nature (1975) 1.11
Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet (1999) 1.10
Intoxication with therapeutic and illicit drug substances and hospital admission to a Dutch university hospital. Neth J Med (2003) 1.09
Glycogenosis type II (acid maltase deficiency). Muscle Nerve Suppl (1995) 1.09
Monoclonal antibodies against human beta-glucocerebrosidase. Eur J Biochem (1983) 1.08
Isolation and characterization of a precursor form of lysosomal alpha-glucosidase from human urine. Eur J Biochem (1984) 1.05
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J (1993) 1.05
Letter: Angiokeratoma corporis diffusum and lysosomal enzyme deficiency. Lancet (1974) 1.02
Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet (1996) 1.01
Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther (2008) 1.00
Solomon's epidermal nevus syndrome (type: linear nevus sebaceus) and hypophosphatemic vitamin D-resistant rickets. Arch Dermatol (1994) 1.00
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem (1995) 0.99
Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest (1991) 0.99
GM1-gangliosidosis. Defective recognition site on beta-galactosidase precursor. J Biol Chem (1986) 0.99
Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother (2001) 0.97
Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet (1998) 0.96
Cotransfer of syntenic human genes into mouse cells using isolated metaphase chromosomes or cellular DNA. Hum Genet (1985) 0.96
Diagnostic features and clinical signs of 21 patients with lissencephaly type 1. Dev Med Child Neurol (1990) 0.96
Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells. J Neurol (1988) 0.96
In-vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands. Equine Vet J (1993) 0.95
The subcellular localization of soluble and membrane-bound lysosomal enzymes in I-cell fibroblasts: a comparative immunocytochemical study. Eur J Cell Biol (1985) 0.95
Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation. Clin Genet (1996) 0.95
Glycogenosis type II: protein and DNA analysis in five South African families from various ethnic origins. Am J Hum Genet (1989) 0.94
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer (2010) 0.94
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency. Biochim Biophys Acta (1982) 0.93
Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord (2007) 0.93
Ganglioside storage, hexosaminidase lability, and urinary oligosaccharides in adult Sandhoff's disease. Neurology (1987) 0.92
A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology (1999) 0.92
Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients. Exp Cell Res (1984) 0.92
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother (2001) 0.92
Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry (2007) 0.92
The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J (2009) 0.92
Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice. Physiol Genomics (2001) 0.91
Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol (1999) 0.91
Carrier detection of Batten disease (juvenile neuronal ceroid-lipofuscinosis). Am J Med Genet (1995) 0.91
Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II. Biochim Biophys Acta (1987) 0.91
Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization. FEBS Lett (1982) 0.90
A quality of life instrument for adolescents with chronic headache. Cephalalgia (1996) 0.90
A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol Chem Neuropathol (1995) 0.90
Characterization of FMR1 proteins isolated from different tissues. Hum Mol Genet (1995) 0.90
Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology (2001) 0.90
Atypical expression of beta-galactosidase deficiency in a child with Hurler-like features but without neurological abnormalities. Clin Genet (1978) 0.90
The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J (1993) 0.90
Mutation detection in glycogen storage-disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun (1997) 0.89
Follow-up of 146 children with epilepsy after withdrawal of antiepileptic therapy. Epilepsia (1988) 0.89
Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. Clin Ther (1999) 0.89
Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol (1995) 0.88
Two genetically different MU-NANA neuraminidases in human leucocytes. Biochem Biophys Res Commun (1983) 0.87
Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. Hum Mutat (1993) 0.87
The distribution of hydrolytic enzyme activities in human fibroblast cultures and their intercellular transfer. Biochem Biophys Res Commun (1978) 0.87
Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology (2006) 0.86
Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet (1999) 0.86
Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle. Pediatr Res (1988) 0.86
The dopamine metabolite 3-methoxytyramine is not a suitable indicator of dopamine release in the rat brain. J Neurochem (1986) 0.86